Proline-rich protein 33 (PRR33)

Proline-rich protein 33 (PRR33) is a muscle-enriched protein highly expressed in human and mouse skeletal muscle and heart. It acts as a positive regulator of muscle differentiation (myogenesis), is upregulated during myoblast differentiation, and is required for normal myofiber size and skeletal muscle function. PRR33 interacts with DESMIN to coordinate cytoskeleton-mitochondria organization during myogenesis. Genetic removal or knockdown of PRR33 impairs myofiber growth, muscle strength, and muscle regeneration. Although mainly studied for its physiological role in muscle, there is currently no evidence to designate PRR33 as a classical therapeutic target, receptor, enzyme, or transporter[1][2][3][7]. Key points: - PRR33 is not a known therapeutic target (receptor, enzyme, transporter) but is studied as a regulator of skeletal muscle biology[1][7]. - Its main known function is in muscle differentiation and mitochondrial organization via interaction with DESMIN[1]. - There are no established drugs or targeted therapies for PRR33; interaction data with chemicals (acrylamide, 2,4-D) is mostly from prediction and not directly therapeutically actionable[4]. - The molecular classification is "Other" as it belongs to a protein family of unknown specific function (DUF4643)[3]. - No biomarker or safety data specific for PRR33 are established. - The gene has been known by several aliases, including C11orf89 and LOC728008[2][6].

Other names

C11orf89LOC728008PRR33proline-rich protein 33proline rich 33